Obsidian Therapeutics

Q2 FY2026 EarningsQ2 FY2026 results missed consensus estimates as Obsidian Therapeutics reported zero revenue and zero net loss for the period from inception (April 10, 2026) to June 30, 2026, while analysts expected a GAAP Net Loss of -$26.3M and a GAAP EPS of -$1.64. The variance is primarily due to the timing of the merger between Gazelle Parent, Galera Therapeutics, and Obsidian, which was only completed on August 3, 2026, leaving the Q2 financials as a shell entity. Post-merger, the company secured a $350M PIPE financing, which is not yet reflected in the June 30 balance sheet.